Apnimed, Inc. (APMD)
Apnimed, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $18.99, up 2.48% on the session, giving a market capitalisation of $790.6M. Its beta of 0.00 implies it has historically moved less than the broad market.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Apnimed, Inc. is most often compared with the following Healthcare names: